July 27 (SeeNews) - Bulgarian veterinary drug maker Biovet said its majority owner Huvepharma and minor shareholder Opportunity 2009 have proposed to acquire the remaining 9.99% stake in the company they do not already own for 9.02 million levs ($5.1 million/4.6 million euro).